H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

In trading on Wednesday, shares of BridgeBio Pharma Inc (Symbol: BBIO) crossed below their 200 day moving average of $28.50, changing hands as low as $28.32 per share. BridgeBio Pharma Inc shares ...

Meeting to be held in Boston on April 8 and in New York on April 9 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

Each dose costs about $119,000, or $476,000 per year. That's more than double the cost of a similar drug from BridgeBio, and more expensive than Pfizer's pills for the same condition. "There are ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biotechnology company with a market capitalization of $6.2 billion focused on developing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...